Market Overview:
The global metastatic ovarian cancer drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of ovarian cancer, rising awareness about early diagnosis and treatment options for ovarian cancer, and the launch of novel drugs for the treatment of metastatic ovarian cancer. Based on type, the global metastatic ovarian cancer drug market can be segmented into E-7449, crizotinib, CMB-305, G-305, LV-305 and others. Based on application, this market can be segmented into clinic settings and hospital settings. Geographically speaking, this market is segmented into North America (the U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain United Kingdom Rest Of Europe), Asia Pacific (China Japan India South Korea Australia New Zealand Rest Of Asia Pacific) and Middle East & Africa (GCC Countries Israel Turkey South Africa Rest Of Middle East & Africa).
Product Definition:
Metastatic ovarian cancer is a type of cancer that begins in the ovaries, but then spreads to other parts of the body. Metastatic ovarian cancer drug is used to treat this type of cancer.
E-7449:
E-7449 is a novel oral drug developed by Eli Lilly and Company for the treatment of advanced ovarian cancer. It is an immunomodulator that works by targeting tumor cells (throughout the body) as well as immune system cells (to fight against tumor). The drug has completed Phase II clinical trial with good safety and efficacy profile, which led to its approval in first half of 2016.
Crizotinib:
Crizotinib (Xeloda) is a drug that belongs to the class of drugs called as Tyrosine Kinase Inhibitors (TKIs). TKIs work by blocking the action of cancer cells that use kinases to multiply and spread. Crizotinib was approved by the FDA in 2013 for treatment of metastatic ovarian cancer.
Application Insights:
The clinic-based segment dominated the overall market in terms of revenue share in 2017. This is due to the increasing number of metastatic ovarian cancer patients and rising awareness about treatment options. According to data published by NCBI, around 15,000 people are diagnosed with Metastatic Ovarian Cancer every year and around 5,000 die due to this disease. Also, according to a study conducted by SEER Cancer Statistics Review for 2014 - 2015 it was found that nearly 54% women aged 65 years or above were diagnosed with M0rstastatic OVCarcies during that period which is an increase from 47% reported for 2012 - 2013.
Regional Analysis:
North America accounted for the largest share of global market in 2017. The presence of key players, favorable government policies and increasing healthcare expenditure are some factors contributing to its growth. In addition, the high adoption rate of new drugs is also expected to drive this region's growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising geriatric population base and improving economic conditions in emerging countries such as China and India. Moreover, a large number of patients present with metastatic disease have few treatment options other than palliative care or comfort care measures which further increases their suffering & distress greatly affecting their quality of life & longevity resulting in increased mortality rate associated with metastic ovarian cancer (IMC).
Growth Factors:
- Increasing incidence of ovarian cancer
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective drugs for metastatic ovarian cancer treatment
- Availability of government funding for research on metastatic ovarian cancer drugs
- Technological advancements in the field of drug development
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Ovarian Cancer Drug Market Research Report
By Type
E-7449, Crizotinib, CMB-305, G-305, LV-305, Others
By Application
Clinic, Hospital, Others
By Companies
Adgero Biopharmaceuticals Inc, Cellceutix Corporation, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited, Northwest Biotherapeutics, Inc., Pfizer Inc., Richter Gedeon Nyrt., Sumitomo Dainippon Pharma Co., Ltd., VG Life Sciences, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Ovarian Cancer Drug Market Report Segments:
The global Metastatic Ovarian Cancer Drug market is segmented on the basis of:
Types
E-7449, Crizotinib, CMB-305, G-305, LV-305, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Adgero Biopharmaceuticals Inc
- Cellceutix Corporation
- Eisai Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- Immune Design Corp.
- Millennium Pharmaceuticals Inc
- MolMed S.p.A.
- Natco Pharma Limited
- Northwest Biotherapeutics, Inc.
- Pfizer Inc.
- Richter Gedeon Nyrt.
- Sumitomo Dainippon Pharma Co., Ltd.
- VG Life Sciences, Inc.
Highlights of The Metastatic Ovarian Cancer Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- E-7449
- Crizotinib
- CMB-305
- G-305
- LV-305
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Ovarian Cancer Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic ovarian cancer is a type of cancer that has spread from the ovaries to other parts of the body. Treatment for metastatic ovarian cancer typically includes chemotherapy and radiation therapy.
Some of the major companies in the metastatic ovarian cancer drug market are Adgero Biopharmaceuticals Inc, Cellceutix Corporation, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited, Northwest Biotherapeutics, Inc., Pfizer Inc., Richter Gedeon Nyrt., Sumitomo Dainippon Pharma Co., Ltd., VG Life Sciences, Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Metastatic Ovarian Cancer Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Metastatic Ovarian Cancer Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Metastatic Ovarian Cancer Drug Market - Supply Chain
4.5. Global Metastatic Ovarian Cancer Drug Market Forecast
4.5.1. Metastatic Ovarian Cancer Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Metastatic Ovarian Cancer Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Metastatic Ovarian Cancer Drug Market Absolute $ Opportunity
5. Global Metastatic Ovarian Cancer Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Type
5.3.1. E-7449
5.3.2. Crizotinib
5.3.3. CMB-305
5.3.4. G-305
5.3.5. LV-305
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Metastatic Ovarian Cancer Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Metastatic Ovarian Cancer Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Metastatic Ovarian Cancer Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Metastatic Ovarian Cancer Drug Demand Share Forecast, 2019-2026
9. North America Metastatic Ovarian Cancer Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Type
9.7.1. E-7449
9.7.2. Crizotinib
9.7.3. CMB-305
9.7.4. G-305
9.7.5. LV-305
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Metastatic Ovarian Cancer Drug Demand Share Forecast, 2019-2026
10. Latin America Metastatic Ovarian Cancer Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Type
10.7.1. E-7449
10.7.2. Crizotinib
10.7.3. CMB-305
10.7.4. G-305
10.7.5. LV-305
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Metastatic Ovarian Cancer Drug Demand Share Forecast, 2019-2026
11. Europe Metastatic Ovarian Cancer Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Type
11.7.1. E-7449
11.7.2. Crizotinib
11.7.3. CMB-305
11.7.4. G-305
11.7.5. LV-305
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Metastatic Ovarian Cancer Drug Demand Share, 2019-2026
12. Asia Pacific Metastatic Ovarian Cancer Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Type
12.7.1. E-7449
12.7.2. Crizotinib
12.7.3. CMB-305
12.7.4. G-305
12.7.5. LV-305
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Metastatic Ovarian Cancer Drug Demand Share, 2019-2026
13. Middle East & Africa Metastatic Ovarian Cancer Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Metastatic Ovarian Cancer Drug Market Size and Volume Forecast by Type
13.7.1. E-7449
13.7.2. Crizotinib
13.7.3. CMB-305
13.7.4. G-305
13.7.5. LV-305
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Metastatic Ovarian Cancer Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Metastatic Ovarian Cancer Drug Market: Market Share Analysis
14.2. Metastatic Ovarian Cancer Drug Distributors and Customers
14.3. Metastatic Ovarian Cancer Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Adgero Biopharmaceuticals Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cellceutix Corporation
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eisai Co., Ltd.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. F. Hoffmann-La Roche Ltd.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Immune Design Corp.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Millennium Pharmaceuticals Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. MolMed S.p.A.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Natco Pharma Limited
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Northwest Biotherapeutics, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pfizer Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Richter Gedeon Nyrt.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Sumitomo Dainippon Pharma Co., Ltd.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. VG Life Sciences, Inc.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook